The earnings transcript for Amgen Inc. presents several key points that could influence the short-term stock performance:

1. **Strong Volume Growth**: Amgen reported a 14% volume growth in the first quarter, driven by strong performance from products like Repatha, EVENITY, BLINCYTO, TEZSPIRE, and TAVNEOS. This indicates a robust demand for their medicines, which is a positive sign[5].

2. **Acquisition and Pipeline**: The company is optimistic about the acquisition of Horizon Therapeutics and the progress in their pipeline, including promising data from various clinical trials. This suggests potential long-term growth opportunities[5].

3. **Financial Performance**: Despite a 2% decline in total revenues due to foreign exchange and other factors, the company saw a 4% increase in product sales excluding these impacts. The non-GAAP EPS was $3.98, and the company raised its 2023 guidance for revenue and EPS, indicating confidence in their financial outlook[5].

4. **Challenges and Competition**: There are some challenges, such as price erosion, inventory adjustments, and competition in certain product segments (e.g., Enbrel, OTEZLA). However, the company is taking steps to address these issues through commercial strategies and product launches[5].

Given these points, the overall tone of the earnings call is positive, highlighting strong volume growth, a robust pipeline, and optimistic guidance. However, there are some short-term challenges related to pricing and competition.

### Conclusion:

The stock is likely to see a positive impact in the short term due to the strong volume growth, raised guidance, and promising pipeline developments, despite some minor headwinds from pricing and competition.

**Rating: 1**